Butterfly Network to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024

Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld ultrasound technology, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024, in New York City.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/07/2024 - 08:05 AM

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)-- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced its participation at the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum in New York City on November 21, 2024.

Joseph DeVivo, President, Chief Executive Officer & Chairman, and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one meetings throughout the day, and Mr. DeVivo will deliver a business overview presentation at 11:00 am ET.

A webcast of the presentation will be posted to the Events & Presentations section of the Butterfly investor website, and available for replay until February 19, 2025.

To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your CG representative.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country.